Steven  Mizell net worth and biography

Steven Mizell Biography and Net Worth

Steve Mizell is executive vice president and chief human resources officer at Merck. He has responsibility for all aspects of human resources including talent acquisition and development, employee wellness, and diversity and inclusion.​

Under Steve’s leadership, Merck has been recognized as a great place to work by Fortune, Fast Company, Working Mother, U.S. Veterans and People magazines. Steve joined Merck in 2018 from Monsanto, where he served as executive vice president, human resources, and was responsible for creating an industry-leading workplace for more than 20,000 employees around the world. Previously, he served as senior vice president and chief corporate resources officer for AdvancePCS, a pharmacy benefit management company, and has also held key human resources management roles at companies across the energy, defense, beverage and technology sectors. ​

Steve is currently a resident of New Jersey and Missouri. He serves on the boards of Allegion Plc. and Group 1 Automotive, and is a former board member of Oshkosh Corporation, where he chaired the human resources committee. Recognized as one of St. Louis’ most influential diverse business leaders, he is a longtime supporter of the National Kidney Foundation, Habitat for Humanity, and Youth in Need.

Steve holds a B.S. from Georgia Institute of Technology and an M.S. in management from Carnegie Mellon University. He is also certified by the National Association of Corporate Directors (NACD).​

What is Steven Mizell's net worth?

The estimated net worth of Steven Mizell is at least $2.39 million as of August 14th, 2023. Mr. Mizell owns 22,935 shares of Merck & Co., Inc. stock worth more than $2,393,726 as of December 11th. This net worth evaluation does not reflect any other assets that Mr. Mizell may own. Learn More about Steven Mizell's net worth.

How old is Steven Mizell?

Mr. Mizell is currently 63 years old. There are 8 older executives and no younger executives at Merck & Co., Inc.. Learn More on Steven Mizell's age.

How do I contact Steven Mizell?

The corporate mailing address for Mr. Mizell and other Merck & Co., Inc. executives is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. Merck & Co., Inc. can also be reached via phone at (908) 740-4000 and via email at [email protected]. Learn More on Steven Mizell's contact information.

Has Steven Mizell been buying or selling shares of Merck & Co., Inc.?

Steven Mizell has not been actively trading shares of Merck & Co., Inc. over the course of the past ninety days. Most recently, Steven Mizell sold 4,250 shares of the business's stock in a transaction on Monday, August 14th. The shares were sold at an average price of $109.01, for a transaction totalling $463,292.50. Following the completion of the sale, the executive vice president now directly owns 22,935 shares of the company's stock, valued at $2,500,144.35. Learn More on Steven Mizell's trading history.

Who are Merck & Co., Inc.'s active insiders?

Merck & Co., Inc.'s insider roster includes Sanat Chattopadhyay (Insider), Frank Clyburn (EVP), Robert Davis (CFO), Richard Deluca (EVP), Kenneth Frazier (Insider), Julie Gerberding (EVP), Clark Golestani (EVP), Michael Holston (EVP), Rita Karachun (VP), Caroline Litchfield (CFO), Steven Mizell (EVP), Johannes Oosthuizen (Insider), Joseph Romanelli (Insider), Ashley Watson (SVP), and Wendell Weeks (Director). Learn More on Merck & Co., Inc.'s active insiders.

Are insiders buying or selling shares of Merck & Co., Inc.?

During the last year, Merck & Co., Inc. insiders bought shares 3 times. They purchased a total of 150 shares worth more than $15,886.16. During the last year, insiders at the sold shares 16 times. They sold a total of 643,192 shares worth more than $73,406,716.13. The most recent insider tranaction occured on November, 9th when insider Johannes Jacobus Oosthuizen sold 2,081 shares worth more than $213,052.78. Insiders at Merck & Co., Inc. own 0.2% of the company. Learn More about insider trades at Merck & Co., Inc..

Information on this page was last updated on 11/9/2023.

Steven Mizell Insider Trading History at Merck & Co., Inc.

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/14/2023Sell4,250$109.01$463,292.5022,935View SEC Filing Icon  
8/3/2023Sell4,500$105.49$474,705.0027,185View SEC Filing Icon  
5/3/2023Sell53,400$119.01$6,355,134.0031,685View SEC Filing Icon  
2/13/2023Sell1,815$109.10$198,016.5033,085View SEC Filing Icon  
2/9/2023Sell5,000$107.00$535,000.0034,900View SEC Filing Icon  
2/6/2023Sell4,436$104.25$462,453.0039,900View SEC Filing Icon  
11/10/2022Sell15,000$101.42$1,521,300.0032,144View SEC Filing Icon  
11/8/2022Sell20,000$101.00$2,020,000.0032,144View SEC Filing Icon  
See Full Table

Steven Mizell Buying and Selling Activity at Merck & Co., Inc.

This chart shows Steven Mizell's buying and selling at Merck & Co., Inc. by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Merck & Co., Inc. Company Overview

Merck & Co., Inc. logo
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. It has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics LP; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV, as well as a collaboration with Bionomics to identify novel a7 nAChR PAMs suitable for the treatment of cognitive disorder; and clinical trial collaboration and supply agreement with Ankyra Therapeutics to evaluate ANK-101 in combination with KEYTRUDA (pembrolizumab) in patients with advanced solid tumors, as well as a clinical trial collaboration and supply agreement with Phanes Therapeutics, Inc. to evaluate PT886 in combination with KEYTRUDA for the treatment of claudin 18.2 positive gastric or gastroesophageal junction adenocarcinomas, as well as a development and commercialization agreement with Daiichi Sankyo Company, Limited to jointly develop and commercialize Daiichi Sankyo's DXd antibody drug conjugate (ADC) candidates. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
Read More

Today's Range

Now: $104.37
Low: $103.57
High: $105.47

50 Day Range

MA: $102.98
Low: $100.17
High: $106.23

2 Week Range

Now: $104.37
Low: $96.36
High: $119.65


7,388,729 shs

Average Volume

7,579,670 shs

Market Capitalization

$264.48 billion

P/E Ratio


Dividend Yield